Fagan AM, Roe CM, Xiong C, Mintun MA, Morris JC, Holtzman DM. Cerebrospinal fluid tau/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults. Arch Neurol. 2007 Mar;64(3):343-9. Epub 2007 Jan 8 PubMed.

AlzBiomarker Database

Meta-Analysis

Curated Study Data

Biomarker
(Source)		 Cohort
(N)		 Measurement
Mean ± SD		 Method;
Assay Name;
Manufacturer		 Diagnostic
Criteria
Aβ40
(CSF)		 AD-
Mild AD
(16)		 9893 ± 3298
pg/mL		 ELISA;
Other/Not Specified;
In-house		 McKhann et al., 1984
Aβ40
(CSF)		 AD-
Very Mild AD
(30)		 9706 ± 3175
pg/mL		 ELISA;
Other/Not Specified;
In-house		 McKhann et al., 1984
Aβ40
(CSF)		 CTRL-
CNC
(90)		 9758 ± 3827
pg/mL		 ELISA;
Other/Not Specified;
In-house
Aβ40
(Plasma)		 AD-
Mild AD
(16)		 214 ± 90.3
pg/mL		 ELISA;
Other/Not Specified;
In-house		 McKhann et al., 1984
Aβ40
(Plasma)		 AD-
Very Mild AD
(30)		 193 ± 82.1
pg/mL		 ELISA;
Other/Not Specified;
In-house		 McKhann et al., 1984
Aβ40
(Plasma)		 CTRL-
CNC
(65)		 191 ± 61.3
pg/mL		 ELISA;
Other/Not Specified;
In-house
Aβ42
(CSF)		 AD-
Mild AD
(16)		 412 ± 134
pg/mL		 ELISA;
Other/Not Specified;
In-house		 McKhann et al., 1984
Aβ42
(CSF)		 AD-
Very Mild AD
(33)		 464 ± 212
pg/mL		 ELISA;
Other/Not Specified;
In-house		 McKhann et al., 1984
Aβ42
(CSF)		 CTRL-
CNC
(90)		 567 ± 207
pg/mL		 ELISA;
Other/Not Specified;
In-house
Aβ42
(Plasma)		 AD-
Mild AD
(16)		 36 ± 37.2
pg/mL		 ELISA;
Other/Not Specified;
In-house		 McKhann et al., 1984
Aβ42
(Plasma)		 AD-
Very Mild AD
(33)		 41 ± 38.9
pg/mL		 ELISA;
Other/Not Specified;
In-house		 McKhann et al., 1984
Aβ42
(Plasma)		 CTRL-
CNC
(65)		 36 ± 29.4
pg/mL		 ELISA;
Other/Not Specified;
In-house
tau-p181
(CSF)		 AD-
Mild AD
(16)		 87 ± 51
pg/mL		 ELISA;
Innotest;
Innogenetics		 McKhann et al., 1984
tau-p181
(CSF)		 AD-
Very Mild AD
(33)		 92 ± 49
pg/mL		 ELISA;
Innotest;
Innogenetics		 McKhann et al., 1984
tau-p181
(CSF)		 CTRL-
CNC
(90)		 62 ± 26
pg/mL		 ELISA;
Innotest;
Innogenetics
tau-total
(CSF)		 AD-
Mild AD
(16)		 606 ± 303
pg/mL		 ELISA;
Innotest;
Innogenetics		 McKhann et al., 1984
tau-total
(CSF)		 AD-
Very Mild AD
(33)		 584 ± 308
pg/mL		 ELISA;
Innotest;
Innogenetics		 McKhann et al., 1984
tau-total
(CSF)		 CTRL-
CNC
(90)		 342 ± 175
pg/mL		 ELISA;
Innotest;
Innogenetics

Recommends

Please login to recommend the paper.

Comments

  1. This study adds further to our ability to exploit chemical and imaging biomarkers for the diagnosis of early AD, while emphasizing the need to identify other biomarkers that may predict who will progress to develop Abeta and tau pathologies prio to the onset of these AD pathologies.

    View all comments by John Trojanowski

  2. Aggregation and deposition of amyloid-β (Aβ) in the brain is thought to be the central event in the pathogenesis of Alzheimer disease (AD). Altered cerebrospinal fluid (CSF) levels of Aβ1-40 and Aβ1-42 and the Aβ42/40 ratio are used as biomarkers to support the clinical diagnosis in AD. Several studies have reported on decreased CSF levels of Aβ1-42, and various studies suggest that Aβ levels might be increased in plasma, including in familial AD forms.

    Despite many studies, many factors, such as genetic polymorphisms, which might be associated with disease or even alter the disease phenotype, are not well understood. These studies are complicated by distinct clinical phenotypes of AD, and even more by the fact that frequently, the diagnosis is done on clinical grounds. Therefore, in complex diseases with heterogeneous phenotypes, new approaches are urgently needed. One way to overcome the problem of clinical heterogeneity is to use intermediate traits, or endophenotypes, which are less heterogeneous than clinical diagnoses and might be more directly affected by genetic variations. In this study, Kauwe et al. analyzed if extreme Aβ levels might be used as an endophenotype for AD.

    The study comprised 191 volunteers participating in a study of aging and dementia. Sixty-four percent of them have a positive family history of AD (one or more first-degree relatives). One hundred forty-three were not demented, 33 percent had a very mild dementia (Clinical Dementia Rating 0.5), and 15 had mild dementia (CDR 1.0). They were studied for Aβ levels in CSF and blood, ApoE genotype, and various clinical characteristics. The levels of Aβ1-40 and Aβ1-42 differed by 10-fold between maximum and minimum in subjects studied. Aβ1-42 levels in CSF significantly decreased with age and increased with CDR scale. Aβ1-40 correlated with sex, but not with age, dementia severity, or ApoE status.

    In contrast to common studies on biomarkers, the authors followed a completely new approach. They hypothesized that extreme Aβ1-40 or Aβ1-42 levels might indicate some specific disease phenotypes and therefore can be used as endophenotypes to characterize AD. To study this, individuals with extreme CSF values of Aβ1-40, Aβ1-42, and Aβ42/40 ratio (top and bottom 5 percent values) were identified for DNA sequencing. Eight genetic variants of PSEN1 were identified in the sample. In one individual, a missense mutation in exon 4, A79V, was identified. This is a known mutation in familial Alzheimer disease that has been previously reported in four families. The carrier is nondemented and has the fifth highest adjusted Aβ1-42 value and the third highest Aβ42/40 ratio in the sample studied. To investigate the consequences of this mutation on Aβ levels, the A79V mutation was introduced into the wild-type PSEN-1 sequence and then transfected into PSEN1/2 knockout mouse embryonic fibroblasts. The Aβ levels and the Aβ42/40 ratio in conditioned media from these cells were significantly higher than the wild-type PSEN-1 sequence, thus suggesting a direct effect of the mutation on Aβ levels.

    The results of the study, which follows a completely novel approach to biomarkers, suggests that CSF or potentially blood levels of certain proteins might be a useful endophenotype for genetic studies in AD and might lead to the identification of atypical disease phenotypes or genetic variations. However, the study opens new questions which are related to the diagnosis of AD, which is most always done on clinical grounds. Since the “typical” CSF pattern seen in AD is a decrease of Aβ1-42, patients with abnormally high levels in CSF, which might also display an atypical clinical presentation, might be missed. As a consequence, a careful follow-up of all suspected cases is needed to solve the question of atypical presentations in AD and potentially to detect novel mutations that might cause AD.

    View all comments by Inga Zerr

Make a Comment

To make a comment you must login or register.

This paper appears in the following:

News

  1. Biomarker Roundup: Collecting Clues from MRIs to RNAs
  2. The Value of Biomarkers—Diagnosis and Genetic Screens
  3. Salzburg: At Five, Amyloid Imaging Registers Growth Spurt
  4. St. Louis: Biomarkers Pre-dementia—Like eFAD, Like LOAD?
  5. Still Early Days for α-synuclein Fluid Marker
  6. Triple Confirmation: AD Footprint in CSF of Cognitively Normal People
  7. AD Immunotherapy: Toward Prevention, DNA-based Vaccines?
  8. Little by Little—Standardizing, Validating Those Biomarkers
  9. Biomarker Duo Signals Mental Decline
  10. Alzheimer Activism: How To Modernize Clinical Trials?
  11. More ADNI Results 2: It’s All About Power
  12. Enabling Technologies for Alzheimer Disease Research: Seventh Bar Harbor Workshop, 2007, Part 2
  13. Speed of Biomarker Changes Herald Alzheimer’s Disease
  14. At AAIC, Researchers Debate Neurogranin's Measure as a Marker

Webinars

  1. Untapped Resource? New Study to Boost Acceptance of CSF Analysis

Research Timeline Event

  1. CSF Aβ, CSF Aβ/tau ratio predicts decline in cognitively normal elderly and FAD mutation carriers

AlzBiomarker

  1. AD vs CTRL : Aβ40 (CSF)
  2. AD vs CTRL : Aβ40 (Plasma and Serum)
  3. CTRL vs AD : Aβ40 (CSF)
  4. CTRL vs AD : Aβ40 (Plasma and Serum)
  5. AD vs CTRL : Aβ42 (CSF)
  6. AD vs CTRL : Aβ42 (Plasma and Serum)
  7. CTRL vs AD : Aβ42 (CSF)
  8. CTRL vs AD : Aβ42 (Plasma and Serum)
  9. AD vs CTRL : tau-p181 (CSF)
  10. CTRL vs AD : tau-p181 (CSF)
  11. AD vs CTRL : tau-total (CSF)
  12. CTRL vs AD : tau-total (CSF)